Annals of Surgical Oncology

, Volume 21, Issue 9, pp 3077–3083 | Cite as

Colorectal Liver Metastases Growth in the Embolized and Non-Embolized Liver After Portal Vein Embolization: Influence of Initial Response to Induction Chemotherapy

  • Romain Pommier
  • Maxime Ronot
  • François Cauchy
  • Sébastien Gaujoux
  • David Fuks
  • Sandrine Faivre
  • Jacques Belghiti
  • Valérie Vilgrain
Hepatobiliary Tumors



To compare tumor progression in both embolized and non-embolized liver lobes after portal vein embolization (PVE) in patients with bilobar colorectal liver metastases (CLM), according to the initial response to induction chemotherapy.


From 2002 to 2012, a total of 42 consecutive patients with bilobar CLM initially treated using induction chemotherapy underwent right PVE to achieve adequate future liver remnant volume. Tumoral and liver parenchyma volumes, as well as their volume variations, were measured on computed tomography before and after PVE in both embolized and non-embolized. Patients were classified as fast (≤6 cycles of induction chemotherapy) and slow (>6 cycles) responders.


Overall, 432 metastases were analyzed in 42 patients. Patients were slow responders in 29 (69 %) cases. Tumoral volume increased in 29 (69 %) cases in the embolized liver (+48 %; p < 0.0001), and in 28 (66 %) cases in the non-embolized liver (+31 %; p < 0.0001). Fast responders had a tumoral volume decrease in both embolized (−4 %) and non-embolized (−9 %) lobes. On the opposite side, slow responders had tumoral volume increase in both embolized (+79 %) and non-embolized (+32 %) lobes. On multivariate analysis, a ‘slow’ response to induction chemotherapy was the only factor associated with tumoral progression in both embolized (p = 0.0012) and non-embolized (p = 0.001) lobes.


Tumor growth after PVE is observed in both embolized and non-embolized liver lobes in most patients but is significantly associated with slow response to induction chemotherapy.


Induction Chemotherapy Colorectal Liver Metastasis Liver Volume Portal Vein Embolization Future Liver Remnant 


Conflicts of interest

Romain Pommier, Maxime Ronot, François Cauchy, Sébastien Gaujoux, David Fuks,Sandrine Faivre, Jacques Belghiti, and Valérie Vilgrain have no conflicts of interest.


  1. 1.
    Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237:208–17.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247:49–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Alberts SR. Update on the optimal management of patients with colorectal liver metastases. Crit Rev Oncol Hematol. 2012;84:59–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg. 2001;88:165–75.PubMedCrossRefGoogle Scholar
  6. 6.
    Dinant S, de Graaf W, Verwer BJ, et al. Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. J Nucl Med. 2007;48:685–92.PubMedCrossRefGoogle Scholar
  7. 7.
    de Baere T, Teriitehau C, Deschamps F, et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol. 2010;17:2081–089.PubMedCrossRefGoogle Scholar
  8. 8.
    Pamecha V, Glantzounis G, Davies N, Fusai G, Sharma D, Davidson B. Long-term survival and disease recurrence following portal vein embolisation prior to major hepatectomy for colorectal metastases. Ann Surg Oncol. 2009;16:1202–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Pamecha V, Nedjat-Shokouhi B, Gurusamy K, Glantzounis GK, Sharma D, Davidson BR. Prospective evaluation of two-stage hepatectomy combined with selective portal vein embolisation and systemic chemotherapy for patients with unresectable bilobar colorectal liver metastases. Dig Surg. 2008;25:387–93.PubMedCrossRefGoogle Scholar
  10. 10.
    Jamdar S, Jegatheeswaran S, Bandara A, Sheen AJ, Siriwardena AK. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg. 2010;97:240–50.CrossRefGoogle Scholar
  11. 11.
    Fuks D, Cook MC, Brehant O, et al. Colorectal carcinoma with potentially resectable metastases: factors associated with the failure of curative schedule. Gastroenterol Clin Biol. 2008;32:390–400.PubMedCrossRefGoogle Scholar
  12. 12.
    Lim C, Cauchy F, Azoulay D, Farges O, Ronot M, Pocard M. Tumour progression and liver regeneration-insights from animal models. Nat Rev Gastroenterol Hepatol. 2013;10:452–62.PubMedCrossRefGoogle Scholar
  13. 13.
    van Gulik TM, van den Esschert JW, de Graaf W, et al. Controversies in the use of portal vein embolization. Dig Surg. 2008;25:436–44.PubMedCrossRefGoogle Scholar
  14. 14.
    de Graaf W, van den Esschert JW, van Lienden KP, van Gulik TM. Induction of tumor growth after preoperative portal vein embolization: is it a real problem? Ann Surg Oncol. 2009;16:423–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Elias D, De Baere T, Roche A, Mducreux, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg. 1999;86:784–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Kokudo N, Tada K, Seki M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology. 2001;34:267–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Barbaro B, Di Stasi C, Nuzzo G, Vellone M, Giuliante F, Marano P. Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE. Acta Radiol. 2003;44:98–102.PubMedGoogle Scholar
  18. 18.
    Hayashi S, Baba Y, Ueno K, et al. Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization. Acta Radiol. 2007;48:721–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Pamecha V, Levene A, Grillo F, Woodward N, Dhillon A, Davidson BR. Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer. 2009;100:617–22.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Maggiori L, Bretagnol F, Sibert A, Paradis V, Vilgrain V, Panis Y. Selective portal vein ligation and embolization induce different tumoral responses in the rat liver. Surgery. 2011;149:496–503.PubMedCrossRefGoogle Scholar
  21. 21.
    Bretagnol F, Maggiori L, Zappa M, Sibert A, Vilgrain V, Panis Y. Selective portal vein embolization and colorectal liver metastases in rat: a new experimental model for tumor growth study. J Surg Res. 2011;171:669–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Cauchy F, Aussilhou B, Dokmak S, et al. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg. 2012;256:746–52.PubMedCrossRefGoogle Scholar
  23. 23.
    Fischer C, Melstrom LG, Arnaoutakis D, et al. Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. JAMA Surg. 2013;148:1103–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Capussotti L, Muratore A, Baracchi F, et al. Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases. Arch Surg. 2008;143:978–82.PubMedCrossRefGoogle Scholar
  25. 25.
    de Baere T, Denys A, Madoff DC. Preoperative portal vein embolization: indications and technical considerations. Tech Vasc Interv Radiol. 2007;10:67–78.PubMedCrossRefGoogle Scholar
  26. 26.
    Tanaka K, Kumamoto T, Matsuyama R, Takeda K, Nagano Y, Endo I. Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases. J Gastrointest Surg. 2010;14:359–68.PubMedCrossRefGoogle Scholar
  27. 27.
    Hoekstra LT, van Lienden KP, Doets A, Busch OR, Gouma DJ, van Gulik TM. Tumor progression after preoperative portal vein embolization. Ann Surg. 2012;256:812–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Denys AL, Abehsera M, Leloutre B, et al. Intrahepatic hemodynamic changes following portal vein embolization: a prospective Doppler study. Eur Radiol. 2000;10:1703–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Archer SG, Gray BN. Vascularization of small liver metastases. Br J Surg. 1989;76:545–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Christophi C, Harun N, Fifis T. Liver regeneration and tumor stimulation: a review of cytokine and angiogenic factors. J Gastrointest Surg. 2008;12:966–80.PubMedCrossRefGoogle Scholar
  31. 31.
    Paschos KA, Bird NC. Liver regeneration and its impact on post-hepatectomy metastatic tumour recurrence. Anticancer Res. 2010;30:2161–70.PubMedGoogle Scholar
  32. 32.
    Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T, Roche A. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterology. 2004;51:1788–91.PubMedGoogle Scholar
  33. 33.
    de Santibanes E, Clavien PA. Playing play-doh to prevent postoperative liver failure: the “ALPPS” approach. Ann Surg. 2012;255:415–7.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Romain Pommier
    • 1
  • Maxime Ronot
    • 1
    • 2
    • 3
  • François Cauchy
    • 2
    • 4
  • Sébastien Gaujoux
    • 2
    • 4
  • David Fuks
    • 2
    • 4
  • Sandrine Faivre
    • 2
    • 5
  • Jacques Belghiti
    • 2
    • 4
  • Valérie Vilgrain
    • 1
    • 2
    • 3
  1. 1.Department of RadiologyBeaujon Hospital (AP-HP), Beaujon University Hospitals Paris Nord Val de SeineClichyFrance
  2. 2.Sorbonne Paris CitéUniversity Paris DiderotParisFrance
  3. 3.INSERM U1149Centre de Recherche Biomédicale Bichat-BeaujonParisFrance
  4. 4.Department of SurgeryBeaujon Hospital (AP-HP), University Hospitals Paris Nord Val de SeineClichyFrance
  5. 5.Department of Medical OncologyBeaujon Hospital (AP-HP), University Hospitals Paris Nord Val de SeineClichyFrance

Personalised recommendations